Academic literature on the topic 'Ethambutol'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Ethambutol.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Ethambutol"
Butov, D. O., M. M. Kuzhko, M. I. Gumeniuk, and T. S. Butova. "Features of infusion chemotherapy with first-line drugs in patients with tuberculous meningitis and HIV." Infusion & Chemotherapy, no. 3.1 (October 11, 2020): 14–15. http://dx.doi.org/10.32902/2663-0338-2020-3.1-10.
Full text&NA;. "Ethambutol." Reactions Weekly &NA;, no. 1266 (August 2009): 18. http://dx.doi.org/10.2165/00128415-200912660-00056.
Full text&NA;. "Ethambutol." Reactions Weekly &NA;, no. 1313 (August 2010): 20. http://dx.doi.org/10.2165/00128415-201013130-00070.
Full text&NA;. "Ethambutol." Reactions Weekly &NA;, no. 455 (June 1993): 8. http://dx.doi.org/10.2165/00128415-199304550-00029.
Full text&NA;. "Ethambutol." Reactions Weekly &NA;, no. 284 (January 1990): 7. http://dx.doi.org/10.2165/00128415-199002840-00026.
Full text&NA;. "Ethambutol." Reactions Weekly &NA;, no. 1119 (September 2006): 12. http://dx.doi.org/10.2165/00128415-200611190-00035.
Full text&NA;. "Ethambutol." Reactions Weekly &NA;, no. 1029 (November 2004): 9. http://dx.doi.org/10.2165/00128415-200410290-00024.
Full text&NA;. "Ethambutol." Reactions Weekly &NA;, no. 1069 (September 2005): 8. http://dx.doi.org/10.2165/00128415-200510690-00022.
Full text&NA;. "Ethambutol." Reactions Weekly &NA;, no. 349 (May 1991): 7. http://dx.doi.org/10.2165/00128415-199103490-00029.
Full text&NA;. "Ethambutol." Reactions Weekly &NA;, no. 557 (July 1995): 6. http://dx.doi.org/10.2165/00128415-199505570-00019.
Full textDissertations / Theses on the topic "Ethambutol"
Pinto, Leonardo Santos Ribeiro [UNESP]. "Síntese, atividade antibacteriana e farmacocinética pré-clínica de pró-fármaco do etambutol com potencial terapêutico para meningite tuberculosa." Universidade Estadual Paulista (UNESP), 2010. http://hdl.handle.net/11449/96243.
Full textCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
O etambutol é preconizado no tratamento da meningite tuberculosa sempre associado a outro fármaco tuberculostático. Mas, embora útil quanto à sua ação, o fármaco não atravessa satisfatoriamente a barreira hematoencefálica. Desta forma, este trabalho propôs a síntese e caracterização estrutural de um pró-fármaco de etambutol (DEREMB) para melhorar a sua penetração no SNC; assim como a realização de estudos de atividade antibacteriana, estabilidade in vitro e ex vivo e, ainda, investigação da disposição cinética do composto; comparando-a com a do etambutol, em ratos wistar (machos, n=20, peso~200g) tratados com dose única via endovenosa (25 mg/kg) e via gavagem (100 mg/kg). A modificação molecular do etambutol alterou a lipossolubilidade do composto, expressa pelo log P, aumentando a possibilidade de penetração no sistema nervoso central, e o aumento da permeabilidade celular, haja vista que o DEREMB apresentou atividade, ainda que menor contra o M. tuberculosis quando comparada ao fármaco matriz. Os resultados obtidos nos ensaios de hidrólise em diferentes pHs (1,2 e 7,4) e na submissão à ação de enzimas plasmáticas permitem observar estabilidade do produto no período de 24 horas. Os parâmetros farmacocinéticos expressos através das médias (IC95%) foram: DEREMB (endovenoso): Cmax (ug/mL)= 10,4; AUC 0-t(ug/mL.min)=252,7; AUC 0-µ(ug/mL.min)= 294,3; Vd (L/kg)=4,3 ; CIT (mL/min/kg)=86,4 ; t ½ (min) =43,1;b (min-1)= 0,021. As baixas concentrações plasmáticas obtidas na administração oral do DEREMB não permitiram o calculo do parâmetros farmacocinéticos por esta via. Apenas os parâmetros Cmax e Vd do DEREMB não apresentaram diferenças estatísticas significativas quando comparados ao etambutol
Ethambutol is a tuberculostatic drug indicated for tuberculous meningitis treatment. But, although useful as for its action, the drug does not cross the blood-brain barrier satisfactorily; certainly reducing its effectiveness in the treatment of the tuberculous meningitis. In this way, this work proposed the synthesis and structural characterization of a prodrug of ethambutol (DEREMB) to improve its penetration in SNC; as well as the accomplishment of studies of antibacterial activity, in vitro and ex vivo stability studies and, still, the investigation of the kinetic disposition of the compound comparing it with the pharmacokinetic profile of ethambutol, in rats wistar (males, n=20, weigth~200g) treated with single iv dose(25 mg/kg) and by gavage (100 mg/kg). The produced prodrug presents a greater lipophilicity – expressed by logp - what could increase its permeation through the blood-brain barrier and its cellular permeability, once the DEREMB presented antimycobacterial activity, although smaller when compared to ethambutol. The in vitro and ex vivo (plasma) hydrolysis studies demonstrates that ethambutol derivative is stable and is not converted to ethambutol in the different pHs which occur in digestory tract or by plasmatic enzymes.. The pharmacokinetic parameters of DEREMB (iv) were: Cmax (ug/mL) = 10,4; AUC 0-t(ug/mL.min)=252,7; AUC 0 - (ug/mL.min) = 294,3; Vd (L/kg)=4,3; CIT (mL/min/kg)=86,4; t ½ (min) =43,1; (min-1) = 0,021. The low plasmatic concentrations obtained in the oral administration of DEREMB did not allow to calculate its pharmacokinetic parameters. Only Cmax and Vd parameters of DEREMB did not present significant statistical differences when compared to ethambutol
Pinto, Leonardo Santos Ribeiro. "Síntese, atividade antibacteriana e farmacocinética pré-clínica de pró-fármaco do etambutol com potencial terapêutico para meningite tuberculosa /." Araraquara : [s.n.], 2010. http://hdl.handle.net/11449/96243.
Full textAbstract: Ethambutol is a tuberculostatic drug indicated for tuberculous meningitis treatment. But, although useful as for its action, the drug does not cross the blood-brain barrier satisfactorily; certainly reducing its effectiveness in the treatment of the tuberculous meningitis. In this way, this work proposed the synthesis and structural characterization of a prodrug of ethambutol (DEREMB) to improve its penetration in SNC; as well as the accomplishment of studies of antibacterial activity, in vitro and ex vivo stability studies and, still, the investigation of the kinetic disposition of the compound comparing it with the pharmacokinetic profile of ethambutol, in rats wistar (males, n=20, weigth~200g) treated with single iv dose(25 mg/kg) and by gavage (100 mg/kg). The produced prodrug presents a greater lipophilicity - expressed by logp - what could increase its permeation through the blood-brain barrier and its cellular permeability, once the DEREMB presented antimycobacterial activity, although smaller when compared to ethambutol. The in vitro and ex vivo (plasma) hydrolysis studies demonstrates that ethambutol derivative is stable and is not converted to ethambutol in the different pHs which occur in digestory tract or by plasmatic enzymes.. The pharmacokinetic parameters of DEREMB (iv) were: Cmax (ug/mL) = 10,4; AUC 0-t(ug/mL.min)=252,7; AUC 0 - (ug/mL.min) = 294,3; Vd (L/kg)=4,3; CIT (mL/min/kg)=86,4; t ½ (min) =43,1; (min-1) = 0,021. The low plasmatic concentrations obtained in the oral administration of DEREMB did not allow to calculate its pharmacokinetic parameters. Only Cmax and Vd parameters of DEREMB did not present significant statistical differences when compared to ethambutol
Orientador: Rosângela Gonçalves Peccinini
Coorientador: Márcia da Silva
Banca: Jean Leandro dos Santos
Banca: Vera Lúcia Lanchote
Mestre
Tshoko, Siphokazi. "Spectroelectrochemical graphene-silver/zinc oxide nanoparticulate phenotype biosensors for ethambutol and pyrazinamide." University of the Western Cape, 2019. http://hdl.handle.net/11394/6842.
Full textTuberculosis (TB), a deadly disease second to HIV/AIDS, is a global health problem. Diagnosis of active tuberculosis is tedious and requires expensive procedures since there is no recognizable method for sole detection of active TB. Although this is a deadly disease, treatment drug toxicity is also an issue that also causes fatalities in diagnosed patients. Therefore, a rapid sensitive and specific diagnostic method is imperative for TB drug management. In this study spectroscopic and/or electrochemical biosensors were developed for the detection and quantification of TB treatment drugs. The biosensors were constructed with electroactive layers of graphene oxide coupled to silver nanoparticles and/or zinc oxide nanoparticles. These nanoparticles coupled with graphene oxide sheets were covalently attached onto the enzymes such as Cytochrome P450-2D6 to achieve the electrochemical detection of the TB treatment drugs and obtain the required electron transfer between the electrode surface and enzyme. The surface morphology of graphene oxide, nanoparticles as well as the green synthesized nanocomposites were achieved using High-Resolution Transmission Electron Microscopy (HRTEM), Atomic Force Microscopy (AFM), and High- Resolution Scanning Electron Microscopy (HRSEM) while the elemental analysis were obtained using Fourier Transform Infrared Spectroscopy (FTIR), Energy Dispersive X-Ray (EDX), Raman spectroscopy and X-Ray diffraction (XRD). Additionally, the optical properties of the developed nanocomposites where further characterised using Small Angle X-ray Scattering (SAXS), Photoluminescence Spectroscopy (PL) and Ultraviolet Spectroscopy (UV-vis). The electrochemical studies were obtained using cyclic voltammetry (CV) and showed an increase in electron conductivity for the green synthesized zinc oxide nanoparticles coupled with graphene oxide (ZnONPs/GO) and silver nanoparticles coupled with graphene oxide (AgNPs/GO) nanocomposite which was an indication that they were suitable as platforms towards biosensor development. Furthermore, amperometric technique was also used for biotransformation of the TB treatment drugs (Ethambutol and Pyrazinamide) in standard solutions of 0.1 M phosphate buffer (pH 7.0). Furthermore, the sensitivity value of 0.0748 μA/μM was determined for the ethambutol biosensor while a value of 0.1715 μA/μM was determined for the pyrazinamide biosensors. Very good detection limits were obtained for the standard solutions of ethambutol and pyrazinamide where a value of 0.02057 nM was determined for ethambutol at concentration linear range of 50 μM – 400 μM. Additionally, a value of 0.8975 x 10-2 nM was determined for pyrazinamide at the concentration linear range of 100 μM – 300 μM. The determined limit of detections have provided a clear indication that these biosensors have potential of being used in human samples since these values are below the peak serum concentrations of these drugs in TB diagnosed patients as reported in literature. This was further confirmed by the limit of quantification values determined for each biosensor where a value of 0.8975 x 10-2 nM was determined for pyrazinamide and a value of 0.02057 nM was determined for ethambutol.
Nyo, Mi Swe Pisamai Kulkanjanatorn. "Spectral characteristics of ethambutol-copper (II) ion complex and its application for quantitative analysis /." Abstract, 2007. http://mulinet3.li.mahidol.ac.th/thesis/2550/cd405/4837396.pdf.
Full textMcIlleron, Helen. "Determinants and consequences of the pharmacokinetics of rifampicin, isoniazid, pyrazinamide and ethambutol in a cohort of tuberculosis patients." Doctoral thesis, University of Cape Town, 2004. http://hdl.handle.net/11427/3290.
Full textA prospectlve pharmacokinetic study was conducted amongst a cohort of 142 patients with tuberculosis (TB) susceptible to rifampicin and isoniazid at Brewelsleloof Hospital, Worcester, in the Western Cape.
MARQUES, Priscila Rocha de Lima. "Efeitos adversos decorrentes do uso de fármacos antituberculose do es-quema quádruplo em serviço de referência da Paraíba." Universidade Federal de Pernambuco, 2015. https://repositorio.ufpe.br/handle/123456789/17703.
Full textMade available in DSpace on 2016-08-18T14:46:04Z (GMT). No. of bitstreams: 2 license_rdf: 1232 bytes, checksum: 66e71c371cc565284e70f40736c94386 (MD5) PRISCILA ROCHA. DISSERTAÇÃO.DIGITAL.pdf: 900577 bytes, checksum: 21461faf83aca3f0a9ae61d40c9c66e3 (MD5) Previous issue date: 2015-08-26
Objetivo: Descrever as reações adversas decorrentes do uso dos fármacos antituberculose do novo esquema preconizado pelo Ministério da Saúde (rifampicina, isoniazida, pirazinamida e etambutol) utilizando comprimidos em dose fixa combinada. Métodos: Estudo descritivo utilizando dados coletados em prontuários médicos de pacientes com tuberculose pulmonar tratados com esquema básico no serviço de referência para tuberculose da Paraíba no período de 2010-2014. Resultados: A amostra foi composta por 257 pacientes com tuberculose pulmonar e houve reação adversa em 71 pacientes (27,63%) totalizando 118 eventos. Esses eventos dividiram-se em reações menores e maiores respectivamente 47,9% e 43,7%, e em 8,5% dos casos, ocorreram ambas as reações. O sistema mais comprometido foi o gastrointestinal em 68,4%, seguido pelo osteoarticular em 13,56%. A hepatotoxicidade foi isoladamente a reação adversa mais comum (30,5%). A toxicidade visual ocorreu em apenas um paciente (0,38%). Houve necessidade de suspender o tratamento em 7,39% e de troca de esquema terapêutico em 1,95%. A frequência de reações adversas observada com o novo esquema foi inferior a de outros estudos nacionais e semelhante aos estudos que utilizaram o esquema antigo. Conclusão: As reações adversas foram principalmente alterações gastrointestinais, sendo a mais comum a hepatotoxicidade. Houve apenas um caso de alteração visual. Na maioria dos casos, não houve necessidade de suspensão nem troca do tratamento.
Objective: To describe the adverse reactions due to the use of antituberculosis drugs under the new regimen recommended by the Health Ministry (rifampicin, isoniazid, pyrazinamide and ethambutol) using tablets in fixed doses combination. Methods: A descriptive study using data collected from medical records of patients with pulmonary tuberculosis treated with basic outline reference service of tuberculosis in Paraíba during the period from 2010 to 2014. Results: The sample consisted of 257 patients with pulmonary tuberculosis, and adverse effects occurred in 71 patients (27.63%) totalizing 118 events. These events were divided into smaller and bigger reactions respectively 47.9% and 43.7%, and in 8.5% of the cases both reactions occurred. The most compromised system was the gastrointestinal at 68.4%, followed by osteoarticular at 13.56%. The hepatotoxicity alone was the most common adverse reaction (30.5%). The visual toxicity occurred in only one patient (0.38%). It was necessary to discontinue the treatment in 7.39% and change the regimen for 1.95%. The frequency of adverse reactions observed with the new scheme was lower than other national studies and similar to studies that used the old scheme. Conclusion: The adverse reactions were mainly gastrointestinal disorders, being hepatotoxicity the most common one, there was only one case of visual change. In most cases there was no need to suspend neither to change the treatment.
Estop, Valérie. "Toxicologie de l'éthambutol." Paris 5, 1988. http://www.theses.fr/1988PA05P139.
Full textNieuwoudt, Liezl-Marié. "The impact of PheroidTM technology on the bioavailability and efficacy of anti-tuberculosis drugs in an animal model / L. Nieuwoudt." Thesis, North-West University, 2009. http://hdl.handle.net/10394/4316.
Full textRassie, Candice. "Electrochemical cytochrome P450 enzymatic biosensors for the determination of the reactivity of TB drugs." University of Western Cape, 2020. http://hdl.handle.net/11394/7235.
Full textTuberculosis (TB) remains a global epidemic despite the fact that treatment has been available since the 1950’s. This disease is highly contagious and spreads via transmission of the Mycobacterium Tuberculosis (MTB) tubercle via coughing, sneezing and spitting. The disease has various side effects including weight loss, fatigue and even death. To date no cure has been found for TB and thus optimisation of treatment is a constant focus in health related research. TB is highly prevalent in South Africa due to the increased level of patients who are co-infected with HIV. Treatment for TB consists of first line drugs including isoniazid (INH), ethambutol (ETH), pyrazinamide (PYR) and rifampicin (RIF). These drugs are highly effective but also produce many adverse drug reactions (ADR’s) over the 6-month course of treatment. These reactions lead to patients not completing the course, losing quality of life and ultimately adding to the development of drug resistant strains of TB. A method of minimising these ADR’s is the development of a phenotype sensor, which is able to determine the metabolic profile of patients. Metabolic profiles play a huge role in the efficacy of treatment by tailoring treatment in order for patients to stay within the therapeutic range of treatment. This would in turn minimise both toxicity and ineffective treatment. Various methods for the quantification of drugs have been developed such as high performance liquid chromatography (HPLC), mass spectrometry (MS) and ultra-violet visible spectroscopy (UV-vis).
2023-12-01
Lopez, Marcos. "Novel Diazeniumdiolates Nitric Oxide Donors and Devices for Biomedical Applications." University of Akron / OhioLINK, 2005. http://rave.ohiolink.edu/etdc/view?acc_num=akron1134746253.
Full textBooks on the topic "Ethambutol"
United Nations Industrial Development Organization. Sectoral Studies Branch. Technical and economic analysis of the manufacture of ethambutol hydrochloride. [Vienna]: The Branch, 1985.
Find full textBook chapters on the topic "Ethambutol"
de Groot, Anton C. "Ethambutol." In Monographs In Contact Allergy, 428–30. Boca Raton: CRC Press, 2022. http://dx.doi.org/10.1201/9781003158004-209.
Full textWang, An-Guor. "Ethambutol-Induced Optic Neuropathy." In Emergency Neuro-ophthalmology, 61–66. Singapore: Springer Singapore, 2018. http://dx.doi.org/10.1007/978-981-10-7668-8_11.
Full textTalwar, Dinesh, Randeep Guleria, Anant Pai, and S. P. Garg. "Do Therapeutic Doses of Ethambutol Cause Optic Nerve Toxicity?" In Advances in Ocular Toxicology, 97–101. Boston, MA: Springer US, 1997. http://dx.doi.org/10.1007/978-1-4615-5937-5_12.
Full textTanabe, Shoko, Kyoko Makita, and Hiroko Koketsu. "Color Vision Test with’ standard Pseudo-Isochromatic Plates Part 2’ for Ethambutol-Induced Optic Neuropathy." In Colour Vision Deficiencies VIII, 59–65. Dordrecht: Springer Netherlands, 1987. http://dx.doi.org/10.1007/978-94-009-4275-2_9.
Full textTapiero, Jeremie. "Ethambutol." In xPharm: The Comprehensive Pharmacology Reference, 1–8. Elsevier, 2008. http://dx.doi.org/10.1016/b978-008055232-3.61715-5.
Full text"Ethambutol." In Meyler's Side Effects of Drugs, 172–78. Elsevier, 2016. http://dx.doi.org/10.1016/b978-0-444-53717-1.00708-3.
Full text"ETHAMBUTOL." In Litt's Drug Eruptions and Reactions Manual, 169. CRC Press, 2014. http://dx.doi.org/10.1201/b15347-74.
Full text"Ethambutol." In Hale’s Medications & Mothers’ Milk™ 2019. New York, NY: Springer Publishing Company, 2018. http://dx.doi.org/10.1891/9780826150356.0374.
Full text"Ethambutol." In Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions, 1282–85. Elsevier, 2006. http://dx.doi.org/10.1016/b0-44-451005-2/00790-7.
Full textKorman, Tony. "Ethambutol." In Kucers' The Use of Antibiotics Sixth Edition, 1570–80. CRC Press, 2010. http://dx.doi.org/10.1201/b13787-126.
Full textConference papers on the topic "Ethambutol"
Batalla-Duran, E., and R. Unsworth. "P2 Using an app to detect early ethambutol toxicity." In British Thoracic Society Winter Meeting 2017, QEII Centre Broad Sanctuary Westminster London SW1P 3EE, 6 to 8 December 2017, Programme and Abstracts. BMJ Publishing Group Ltd and British Thoracic Society, 2017. http://dx.doi.org/10.1136/thoraxjnl-2017-210983.144.
Full textGrosset, Jacques H. E., Ming Zhang, Si-Yang Li, Charles Peloquin, Deepak Almeida, Sandeep Tyagi, Paul Converse, and Eric L. Nuermberger. "In Constrast To Isoniazid, Ethambutol Does Not Antagonize The Rifampin - Pyrazinamide Combination." In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a1832.
Full textTorrelles, Jordi, Nannan Zhang, Kay-Hooi Khoo, and Delphi Chatterjee. "DEFINING THE MECHANISM OF THE BIOCHEMICAL AND GENETIC BASIS OF ETHAMBUTOL-RESISTANCE." In XXIst International Carbohydrate Symposium 2002. TheScientificWorld Ltd, 2002. http://dx.doi.org/10.1100/tsw.2002.687.
Full textŞişmanlar Eyuboglu, Tuğba, Sevgi Yasar Durmus, Selin Sahin Karamert, Ayse Kaman, Turkan Teke, Fatma Nur Oz, and Gonul Tanır. "Reversible Color Blindness due to Ethambutol in a Pediatric Patient with Pulmonary Tuberculosis." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa1063.
Full textAraújo, Hugo, Mário Diniz, Željko Petrovski, Miguel Santos, and Luís Branco. "Ethambutol based organic salts and ionic liquids as effective drug formulations against tuberculosis." In 7th International Electronic Conference on Medicinal Chemistry. Basel, Switzerland: MDPI, 2021. http://dx.doi.org/10.3390/ecmc2021-11566.
Full textKwon, Byoung Soo, Yong Pil Chong, Mi-Na Kim, Heungsup Sung, Younsuck Koh, Woo-Sung Kim, Jin-Woo Song, et al. "In vitro susceptibility to rifampin and ethambutol and treatment outcome in MAC lung disease." In ERS International Congress 2018 abstracts. European Respiratory Society, 2018. http://dx.doi.org/10.1183/13993003.congress-2018.pa343.
Full textAndo, T., H. Kage, Y. Matsumoto, and T. Nagase. "Lower Dose of Ethambutol Reduce Ocular Toxicity Without Compromising Efficacy for Pulmonary Mycobacterium Avium Complex Disease." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2538.
Full textKuzhko, Mykhailo, Ljubomyr Procyk, Leonid Grechanyk, Mykola Gumenjuk, Nataliia Hulchuk, and Oksana Avramchuk. "Efficacy of moxifloxacin instead of ethambutol in the intensive phase of therapy in newly diagnosed pulmonary TB." In ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa2715.
Full textAguilera, Claudine, Daniel H. Goodman, and Tze-Ming Chen. "A Confirmed Case Of Mycobacterium Gordonae With Clinical, Microbiologic, And Radiographic Improvement on Clarithromycin, Rifampin, And Ethambutol Treatment." In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a3164.
Full textButova, Tatiana, Mykhailo Kuzhko, Mykola Gumeniuk, and Dmytro Butov. "Efficacy of intravenous isoniazid, rifampin and ethambutol administration in patients with failed treatment of tuberculosis and malabsorption syndrome." In ERS International Congress 2020 abstracts. European Respiratory Society, 2020. http://dx.doi.org/10.1183/13993003.congress-2020.495.
Full text